Gliosarcoma clinical trials
The registry lists 236 studies for Gliosarcoma across more than 10 countries. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 138
- Terminated
- 48
- Active, not recruiting
- 19
- Recruiting
- 15
- Withdrawn
- 9
- Status unknown
- 5
Phase
- Phase 2
- 125
- Phase 1
- 123
- Early Phase 1
- 8
- Phase 3
- 8
Where
- United States
- 223
- Canada
- 15
- United Kingdom
- 4
- Switzerland
- 4
- Australia
- 4
- Germany
- 4
Who runs them
National Cancer Institute (NCI) (80) · Duke University (17) · M.D. Anderson Cancer Center (13) · Jonsson Comprehensive Cancer Center (6) · City of Hope Medical Center (6) · Mayo Clinic (6) · University of California, San Francisco (4) · Pediatric Brain Tumor Consortium (4)
Studies
Recruiting first, then most recently updated. Showing 50 of 236 — search for more.
- MSC-DNX-2401 in Treating Patients With Recurrent High-Grade GliomaRecruitingNCT03896568Phase 11 country
- ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG TrialRecruitingNCT07089641Phase 11 country
- A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent GliomaRecruitingNCT05698524Phase 11 country
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaRecruitingNCT06934889Phase 11 country
- Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMRecruitingNCT04991870Phase 11 country
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 11 country
- Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudyRecruitingNCT069546361 country
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaRecruitingNCT05864534Phase 21 country
- Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaNot yet recruitingNCT07422363Phase 1
- A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.RecruitingNCT07134842Phase 11 country
- GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaRecruitingNCT07301268Phase 21 country
- Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueRecruitingNCT057569851 country
- Study of Pembrolizumab and M032 (NSC 733972)RecruitingNCT05084430Phase 1/21 country
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaRecruitingNCT05465954Phase 21 country
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsRecruitingNCT04541082Phase 11 country
- Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®RecruitingNCT05363826Phase 11 country
- Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT03174197Phase 1/21 country
- Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaActive, not recruitingNCT03197506Phase 21 country
- DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent GlioblastomaActive, not recruitingNCT03115333Not applicable1 country
- Pembrolizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02337686Phase 21 country
- Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/21 country
- Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 11 country
- Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated GlioblastomaActive, not recruitingNCT05095376Phase 32 countries
- A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaActive, not recruitingNCT06614855Phase 11 country
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT02455557Phase 21 country
- A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasActive, not recruitingNCT01837862Phase 1/21 country
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/32 countries
- Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingNCT04555577Phase 11 country
- Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)SuspendedNCT06806228Phase 13 countries
- Mycophenolate Mofetil Combined With Radiation Therapy in GlioblastomaActive, not recruitingNCT04477200Phase 11 country
- Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasActive, not recruitingNCT02192359Phase 11 country
- Natural Progesterone for the Treatment of Recurrent GlioblastomaTerminatedNCT05091866Early Phase 11 country
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/31 country
- Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 21 country
- Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent GlioblastomaActive, not recruitingNCT04528680Phase 1/21 country
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 13 countries
- Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and GlioblastomaTerminatedNCT02942264Phase 1/21 country
- Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04216329Phase 11 country
- Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 11 country
- Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With GlioblastomaCompletedNCT03746080Phase 21 country
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedNCT03107780Phase 11 country
- Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant GliomaActive, not recruitingNCT02062827Phase 11 country
- Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant GliomaCompletedNCT01165632Early Phase 11 country
- Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior BevacizumabCompletedNCT01931098Phase 21 country
- Spectroscopic MRI-Guided Radiation Therapy Planning in GlioblastomaCompletedNCT03137888Phase 21 country
- Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated GlioblastomaCompletedNCT03452930Phase 11 country
- Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyTerminatedNCT01430351Phase 11 country
- Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasCompletedNCT02186509Phase 11 country
- ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma MultiformeActive, not recruitingNCT01903330Phase 21 country
- NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent GlioblastomaCompletedNCT01894061Phase 21 country